Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05800366 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
A Phase 2 study of Lymphoma and Lymphoma, Large B-Cell, Diffuse, sponsored by Jennifer Crombie, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 3
- Study locations
NCT05800366: Recruiting Phase 2 study of Lymphoma and Lymphoma, Large B-Cell, Diffuse, sponsored by Jennifer Crombie, MD.
NCT05800366 is a Phase 2 study of Lymphoma and Lymphoma, Large B-Cell, Diffuse that is actively recruiting participants, run by Jennifer Crombie, MD. The registered enrollment target is 41 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05800366, a Phase 2 study of Lymphoma and Lymphoma, Large B-Cell, Diffuse, is actively recruiting participants, sponsored by Jennifer Crombie, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma. The names of the treatment interventions involved in this study are: * Glofitamab (T-cell bispecific antibody) * Polatuzumab (antibody-drug conjugate) * R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)
Primary Outcome
The complete response (CR) Rate is the proportion of participants achieving CR based on Lugano criteria defined per protocol section 11.1.1 for target lesions.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Glofitamab
- DRUG Rituximab
- DRUG Doxorubicin Hydrochloride
- DRUG Polatuzumab
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Florida
- University of Miami Sylvester Cancer Center - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-04-06 |
| Est. Completion | 2029-09-15 |
| Phase | Phase 2 |
What NCT05800366 shows while recruiting
NCT05800366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05800366 reports a single indexed study location in Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT05800366 about?
NCT05800366 is a clinical study titled "A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma". The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma. The names of the treatment interventions involved in this study are: * Glofitamab (T-ce...
What is the current status of trial NCT05800366?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2023-04-06. Estimated completion is 2029-09-15.
What conditions does trial NCT05800366 study?
This clinical trial studies the following conditions: Lymphoma, Lymphoma, Large B-Cell, Diffuse.
What interventions are being tested in trial NCT05800366?
The interventions under investigation include: Cyclophosphamide (DRUG), Glofitamab (DRUG), Rituximab (DRUG), Doxorubicin Hydrochloride (DRUG), Polatuzumab (DRUG).
Who is sponsoring clinical trial NCT05800366?
This trial is sponsored by Jennifer Crombie, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05800366 being conducted?
This trial has 3 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05800366's enrollment target sits among peer trials
41 172nd of 299 higher than 127 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI